Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Outlook Therapeutics Inc
OTLK | US
0.21
USD0.01
6.18%
OTLK | US
About Outlook Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
07/04/2026
Close
0.21
Open
0.21
High
0.22
Low
0.18
Outlook Therapeutics Inc. a late clinical-stage biopharmaceutical company focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010 an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co. Ltd. The company was formerly known as Oncobiologics Inc. and changed its name to Outlook Therapeutics Inc. in November 2018. Outlook Therapeutics Inc. was incorporated in 2010 and is based in Iselin New Jersey.
View LessOTLK | US
Risk
163.9
Sharpe
-0.67
Luna's Score
51/100
Recommendation
Hold
Luna says (OTLK | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
207.3%1 month
163.9%3 months
117.9%6 months
140.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
2.85
Price to book
10.19
Debt to equity
-0.39
Debt to assets
0.69
Ent. to EBITDA
-4.13
Ent. to rev.
26.10
PEG
-
Other Fundamentals
EBITDA
-61.19M
MarketCap
5.04M
MarketCap(USD)
5.04M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
658.30
Ret. on equity
-3.65
Short ratio
9.53
Short perc.
18.34
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.07
Range1M
0.30
Range3M
0.48
Volumes: Market Activity
Rel. volume
2.31
Price X volume
1.81M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.13 | - | Cheaper |
| Ent. to Revenue | 26.10 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 10.19 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 117.92 | - | Riskier |
| Debt to Equity | -0.39 | -1.23 | Expensive |
| Debt to Assets | 0.69 | 0.25 | Expensive |
| Market Cap | 5.04M | - | Emerging |
